Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.

被引：2
|
作者：
Fan, Bin
Goyal, Lipika
Lowery, Maeve Aine
Pandya, Shuchi Sumant
Manyak, Erika
Le, Kha
Jiang, Liewen
Auer, Julia
Dai, David
机构：
[1] Agios Pharmaceut Inc, Cambridge, MA USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4082
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
    Fan, Bin
    Le, Kha
    Manyak, Erika
    Liu, Hua
    Prahl, Malia
    Bowden, Chris J.
    Biller, Scott
    Agresta, Sam
    Yang, Hua
    BLOOD, 2015, 126 (23)
  • [2] PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES
    Fan, B.
    Chen, Y.
    Wang, F.
    Yen, K.
    Utley, L.
    Prahl, M.
    Colby, K.
    Straley, K.
    Bowden, C.
    Biller, S.
    Agresta, S.
    Yang, H.
    HAEMATOLOGICA, 2015, 100 : 218 - 218
  • [3] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Pandya, Shuchi Sumant
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Yang, Hua
    Dai, David
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies
    Le, Kha
    Wada, Russ
    Dai, David
    Fan, Bin
    Liu, Guowen
    Liu, Hua
    Attar, Eyal C.
    Agresta, Samuel V.
    Yang, Hua
    BLOOD, 2018, 132
  • [5] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
    de Botton, S.
    Pollyea, D. A.
    Stein, E. M.
    DiNardo, C.
    Fathi, A. T.
    Roboz, G. J.
    Collins, R.
    Swords, R. T.
    Flinn, I.
    Altman, J. K.
    Tallman, M. S.
    Kantarjian, H.
    Colby, K.
    Fan, B.
    Goldwasser, M.
    Prahl, M.
    Agresta, S.
    Stone, R. M.
    HAEMATOLOGICA, 2015, 100 : 214 - 215
  • [6] Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
    Lowery, Maeve A.
    Burris, Howard A., III
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer S.
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Fan, Bin
    Aguado-Fraile, Elia
    Choe, Sung
    Bin Wu
    Gliser, Camelia
    Agresta, Samuel, V
    Pandya, Shuchi S.
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 711 - 720
  • [7] Ivosidenib (IVO; AG-120) in IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Updated Results from a Phase 1 Study
    DiNardo, Courtney D.
    Foran, James M.
    Watts, Justin M.
    Stein, Eytan M.
    De Botton, Stephane
    Fathi, Amir T.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Stone, Richard M.
    Patel, Prapti A.
    Tallman, Martin S.
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Dai, David
    Fan, Bin
    Yen, Katherine E.
    Kapsalis, Stephanie K.
    Hickman, Denice
    Agresta, Samuel V.
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S340 - S340
  • [8] Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
    Foran, James M.
    DiNardo, Courtney D.
    Watts, Justin M.
    Stein, Eytan M.
    De Botton, Stephane
    Fathi, Amir T.
    Prince, Gabrielle T.
    Stein, Anthony
    Stone, Richard M.
    Patel, Prapti A.
    Tallman, Martin S.
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Fan, Bin
    Yen, Katharine E.
    Oluyadi, Abdulafeez
    Winkler, Thomas
    Hickman, Denice
    Agresta, Samuel V.
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [9] Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
    Dai, David
    Dinardo, Courtney Denton
    Stein, Eytan
    de Botton, Stephane
    Attar, Eyal C.
    Liu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors.
    Gangadhar, Tara C.
    Beumer, Jan Hendrik
    Espinoza-Delgado, Igor
    Anyang, Bean N.
    Karovic, Sanja
    Sharma, Manish
    Wen, Yujia
    Janisch, Linda A.
    Kindler, Hedy Lee
    Nanda, Rita
    Karrison, Theodore
    Ratain, Mark J.
    Maitland, Michael L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345